Ustekinumab for the treatment of adults with moderate to severe psoriasis

  • Technology appraisal guidance
  • TA180
  • Published: 
  • Last updated: 
Download guidance (PDF)

8 Sources of evidence considered by the committee

A. The evidence review group (ERG) report for this appraisal was prepared by Southampton Health Technology Assessments Centre, The University of Southampton:

  • Gospodarevskaya E, Picot J, Cooper K et al. Ustekinumab for the treatment of moderate to severe psoriasis, March 2009

B. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to give their expert views. Organisations listed in I, II and III also have the opportunity to appeal against the final appraisal determination.

I) Manufacturer/sponsor:

  • Janssen-Cilag

II) Professional/specialist and patient/carer groups:

  • British Association of Dermatologists

  • Psoriasis and Psoriatic Arthritis Alliance

  • Psoriasis Association

  • Royal College of Physicians

  • Royal College of Nursing

III) Other consultees:

  • Department of Health

  • Dorset PCT

  • Welsh Assembly Government

  • Sandwell PCT

IV) Commentator organisations (did not provide written evidence and without the right of appeal):

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Southampton Health Technology Assessments Centre, The University of Southampton

  • National Institute for Health Research (NIHR) Health Technology Assessment (HTA) Programme

  • NHS Quality Improvement Scotland

  • Abbott Laboratories

  • Merck Serono

  • Schering-Plough

  • Wyeth Pharmaceuticals

C. The following individuals were selected from clinical specialist and patient expert nominations from the non-manufacturer/sponsor consultees and commentators. They gave their expert personal view on ustekinumab for moderate to severe psoriasis by attending the initial Committee discussion and providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Professor Alex Anstey, Consultant Dermatologist, nominated by The British Association of Dermatologists – clinical specialist

  • Professor Jonathan Barker, Consultant Dermatologist, nominated by The British Association of Dermatologists – clinical specialist

  • Mr Ray Jobling, nominated by The Psoriasis Association – patient expert

  • Miss Helen McAteer, nominated by The Psoriasis Association – patient expert